D. Boral Capital Maintains Buy on Turn Therapeutics, Maintains $8 Price Target
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and maintains $8 price target.
D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and maintains $8 price target.